Marcos M. S.
- Country
- Spain
- Department
- Oncology
Research Overview
- A Phase Study of PHN-012 in Patients With Advanced Solid Tumors
- Efficacy and Safety of PF-08634404 and Combination Therapy Versus Bevacizumab and Combination Therapy in Treatment-Naïve Participants With Metastatic Colorectal Cancer
- Randomized Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Versus Trifluridine/Tipiracil + Bevacizumab in Treated Metastatic Colorectal Cancer
Data & Insights
Has run more than one trial at 100 of 315 partner sites.
Specializations
Breast Cancer and HER2-Directed Therapy
Clinical research centers on early breast cancer, metastatic breast cancer, and hormone receptor-positive, HER2-negative or HER2-positive disease, with interest in PIK3CA, BRCA, and ESR1-linked treatment strategies.
- Endocrine therapy combinations
- HER2-targeted treatment
- Neoadjuvant and adjuvant breast cancer care
- Metastatic breast cancer with CNS involvement
Work also extends to triple-negative breast cancer, brain metastases, and recurrence-focused approaches in biologically selected breast cancer populations.
Genitourinary Oncology
The investigator is actively involved in trials for prostate cancer, bladder cancer, urothelial carcinoma, and renal cell carcinoma, covering both localized and advanced disease.
- Metastatic castration-resistant prostate cancer
- Muscle-invasive bladder cancer
- Upper tract urothelial carcinoma
- Advanced renal cell carcinoma
Therapeutic interests include androgen receptor pathway strategies, immune checkpoint inhibition, and perioperative treatment for urothelial malignancies.
Lung Cancer and Thoracic Malignancies
Research activity includes non-small cell lung cancer, small cell lung cancer, and molecularly defined thoracic tumors, with attention to EGFR-, KRAS G12C-, and MET-altered disease.
- Advanced non-small cell lung cancer
- Extensive-stage small cell lung cancer
- Resectable lung cancer
- Targeted and immunotherapy combinations
Clinical interests also include treatment for post-immunotherapy progression and PD-L1-selected lung cancer populations.
Gynecologic Oncology
Trial involvement covers endometrial cancer, ovarian cancer, and cervical cancer, including recurrent, metastatic, and platinum-resistant settings.
- Advanced endometrial cancer
- Platinum-resistant ovarian cancer
- Advanced epithelial ovarian carcinoma
- Locally advanced cervical cancer
Areas of interest include PARP inhibitor-based strategies, immunotherapy, and biomarker-driven approaches in HER2-expressing or MMR-deficient tumors.
Melanoma, Head and Neck Cancer, and Solid Tumors
The investigator is also involved in broader solid tumor research, including melanoma, head and neck squamous cell carcinoma, colorectal cancer, and gastrointestinal stromal tumor.
- Advanced melanoma
- Head and neck squamous cell carcinoma
- Metastatic colorectal cancer
- Advanced solid tumors
Therapeutic focus includes adjuvant and perioperative immunotherapy, targeted agents, and treatment innovation across biomarker-defined tumor groups.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.